Targeting Glycans on Human Pathogens for Vaccine Design

Area of Science:

• Immunology
• Glycobiology
• Vaccinology

Background:

• Glycosylation, a key post-translational modification, is crucial for protein structure, stability, and function.
• Pathogen surface carbohydrates (glycans) can be immunogenic, eliciting protective glycan-binding antibodies during infection.
• Existing carbohydrate vaccines target bacterial pathogens, while others against viruses, parasites, and fungi are under development.

Purpose of the Study:

• To review the role of glycosylation in host-pathogen interactions and immune responses.
• To discuss the development of carbohydrate vaccines targeting various human pathogens.
• To explore challenges and progress in inducing cross-reactive carbohydrate-targeting antibodies.

Main Methods:

• Review of scientific literature on glycosylation, immunology, and vaccine development.
• Analysis of successful and developmental carbohydrate vaccine strategies.
• Discussion of antibody responses to glycan antigens.

Main Results:

• Successful carbohydrate vaccines exist for bacterial pathogens like Haemophilus influenzae type b, Streptococcus pneumoniae, and Neisseria meningitidis.
• Progress in developing vaccines against HIV-1, Dengue virus, Hepatitis C virus, Plasmodium, and Candida is ongoing.
• Glycan structures, when conjugated to carrier proteins, can elicit potent and protective immune responses.

Conclusions:

• Carbohydrate vaccines represent a promising strategy for combating infectious diseases.
• Overcoming challenges in inducing broadly reactive and protective antibodies is key to advancing carbohydrate vaccine development.
• Continued research is essential for the successful implementation of carbohydrate vaccines against a wider range of pathogens.